<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01868269</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2011-02</org_study_id>
    <nct_id>NCT01868269</nct_id>
  </id_info>
  <brief_title>Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)</brief_title>
  <official_title>Multinational European Trial for Children With the Opsoclonus Myoclonus Syndrome / Dancing Eye Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The OMS/DES study is a multinational European Trial for Children with the Opsoclonus&#xD;
      Myoclonus Syndrome / Dancing Eye Syndrome.&#xD;
&#xD;
      This trial brought on the way by specialists of the EPNS (European Paediatric Neurology&#xD;
      Society), the GPOH (Gesellschaft für Pädiatrische Hematologic und Oncologie) and the SIOPEN&#xD;
      (SIOP (International Society Oncology Pediatric) Europe Neuroblastoma).&#xD;
&#xD;
      This protocol will investigate an escalating treatment schedule starting with a&#xD;
      corticosteroid standard treatment with dexamethasone pulses (first step), which is followed,&#xD;
      if response has been inadequate after 3 months of treatment, by the addition of CP (second&#xD;
      step) and, if still no sufficient improvement, by the replacement of CP by Rituximab (third&#xD;
      step). Treatment intensification is decided on the basis of standardized scoring of OMS/DES&#xD;
      severity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 18, 2013</start_date>
  <completion_date type="Anticipated">April 2031</completion_date>
  <primary_completion_date type="Anticipated">February 2027</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The response to treatment schedule as defined by the percentage of patients with disappearance of all symptoms.</measure>
    <time_frame>at 48 weeks after treatment start</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Opsoclonus Myoclonus Syndrome</condition>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>Dexamethasone Cyclophosphamide Rituximab</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone acetate</intervention_name>
    <description>First step:&#xD;
immunosuppressive treatment with dexamethasone</description>
    <arm_group_label>Dexamethasone Cyclophosphamide Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone and cyclophosphamide</intervention_name>
    <description>second step (in case of insufficient response): immunosuppressive treatment with dexamethasone and cyclophosphamide</description>
    <arm_group_label>Dexamethasone Cyclophosphamide Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone and rituximab</intervention_name>
    <description>third step (in case of insufficient response): immunosuppressive treatment with dexamethasone and rituximab</description>
    <arm_group_label>Dexamethasone Cyclophosphamide Rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children with newly diagnosed OMS/DES either NB-pos or NB-neg.&#xD;
&#xD;
        Three out of the following four components are necessary for the diagnosis of OMS/DES:&#xD;
&#xD;
          -  Opsoclonus or ocular flutter (but not nystagmus)&#xD;
&#xD;
          -  Ataxia and/or myoclonus&#xD;
&#xD;
          -  Behavioural change and/or sleep disturbance&#xD;
&#xD;
          -  Neuroblastoma The diagnosis of OMS/DES may be difficult in some patients. Opsoclonus,&#xD;
             in particular, may be intermittent or late in onset. A video example will be available&#xD;
             at www.dancingeyes.org.uk. If uncertain, please contact the national coordinator for&#xD;
             support in interpreting clinical features.&#xD;
&#xD;
               -  Age 6 months or over up to less than 8 years (&lt; 8th birthday) The date of&#xD;
                  diagnosis of OMS/DES is the date on which a doctor confirms the condition to be&#xD;
                  OMS/DES. The date of symptom onset needs also to be documented.&#xD;
&#xD;
               -  Treatment start with the standard corticosteroid treatment with dexamethasone&#xD;
                  pulses as proposed by the guidelines given in this trial protocol (see 11.10,&#xD;
                  page 71).&#xD;
&#xD;
               -  In patients with presumed NB-neg OMS/DES, neuroblastoma must be excluded&#xD;
                  according the guidelines of this trial (see chapter 4.4.1.4, page 30, and&#xD;
                  appendix 11.9, page 70)&#xD;
&#xD;
               -  Documented informed consent for treatment and enrolment in the trial by parents /&#xD;
                  legal representatives.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        •Patients with opsoclonus, myoclonus or ataxia caused by other identified disease (e.g.&#xD;
        current active CNS infection, neurometabolic disorder or demyelination).&#xD;
&#xD;
        An identified viral precursor is not an exclusion criterion.&#xD;
&#xD;
          -  prior or parallel use of chemotherapy (other than required for treatment of the&#xD;
             neuroblastoma)&#xD;
&#xD;
          -  Corticoid steroid for OMS/DES or other reasons lasting 14 days or more immediately&#xD;
             before treatment start according the standard treatment proposed (treatment with&#xD;
             corticosteroids for less than 14 days will be allowed)&#xD;
&#xD;
          -  contre-indication of use of one of the experimental study drug (cf Summary of Product&#xD;
             Characteristics used in this study)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gudrun Schleiermacher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Anna Kinderkrebsforschung e.V. CHILDREN'S CANCER RESEARCH INSTITUTE</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Bicetre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <state>LE Kremlin Bicetre</state>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <state>Lille Cedex</state>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <state>LYON Cedex 08</state>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopita D'Enfants de La Timone</name>
      <address>
        <city>Marseille</city>
        <state>Marseille Cedex 5</state>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <state>Montpellier Cedex 4</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chr de Nantes</name>
      <address>
        <city>Nantes</city>
        <state>Nantes Cedex01</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Nice Archet 2</name>
      <address>
        <city>Nice</city>
        <state>NICE Cedex 03</state>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Trousseau</name>
      <address>
        <city>Paris</city>
        <state>Paris Cedex 12</state>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Hopital Sud</name>
      <address>
        <city>Rennes</city>
        <state>Rennes Cedex 02</state>
        <zip>35056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Rouen</name>
      <address>
        <city>Rouen</city>
        <state>Rouen Cedex</state>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU DE STRASBOURG HOPITAL Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <state>Strasbourg Cedex</state>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Toulouse Hopital Des Enfants</name>
      <address>
        <city>Toulouse</city>
        <state>Toulouse Cedex 9</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chr Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU CAEN</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu D'Estaing</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38045</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU LA REUNION Site Félix Guyon</name>
      <address>
        <city>Saint-denis</city>
        <zip>97400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Saint Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Tours Hopital Clocheville</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Nancy Brabois</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G. Gaslini Institut</name>
      <address>
        <city>Genova</city>
        <zip>16148</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Fundación para la Formación e Investigación Sanitarias de la Región de Murcia</name>
      <address>
        <city>El Palmar</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Lund</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätskinderklinik</name>
      <address>
        <city>Bern</city>
        <zip>CH 3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinderspital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>0X3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 27, 2013</study_first_submitted>
  <study_first_submitted_qc>May 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2013</study_first_posted>
  <last_update_submitted>August 6, 2020</last_update_submitted>
  <last_update_submitted_qc>August 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Opsoclonus-Myoclonus Syndrome</mesh_term>
    <mesh_term>Myoclonus</mesh_term>
    <mesh_term>Ocular Motility Disorders</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

